Halia Therapeutics Announces Positive Phase 2a Data for Ofirnoflast in Lower-Risk MDS at ASH 2025
– New findings demonstrate a 72% HI-E response rate at Week 16…
Fulcrum Therapeutics Announces Positive Initial Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
December 06, 2025 17:30 ET  | Source: Fulcrum Therapeutics, Inc. ― Clear…
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies
The formal safety review of Cohort 3 (5ug/kg/day) has been successfully completed…
Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinsons Disease
Event to be held October 14th at 4 p.m. EST October 09,…
ACKO’s Grand Traffic Challan Report: Delhi Leads E Challan Fines
NEW DELHI, Oct. 6, 2025 /PRNewswire/ -- ACKO's Grand Traffic Challan Report…
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or…
BioAge Labs to Present Preclinical Data on APJ Agonism for Diabetic Obesity and Heart Failure at the American Diabetes Association (ADA) 85th Scientific Sessions
June 21, 2025 18:00 ET Â | Source: BioAge Labs, Inc. Treatment with…
Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…